Enikeev Dmitry, Morozov Andrey, Babaevskaya Diana, Bazarkin Andrey, Malavaud Bernard
Department of Urology, Medical University of Vienna, 1090 Vienna, Austria.
Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia.
Cancers (Basel). 2022 Aug 4;14(15):3802. doi: 10.3390/cancers14153802.
The purpose of the review is to summarize the recent data on circulating tumor cells (CTC) use in clinical practice. We performed a systematic literature search using two databases (Medline and Scopus) over the past five years and the following terms: (CTC OR "circulating tumor cells" OR "liquid biopsy") AND prostate. The primary outcome was CTC predictive value for prostate cancer (PC) progression and survival. The secondary outcomes were the CTC predictive value for therapy response and the results of CTC detection depending on the assessment method. In metastatic PC, the CTC count showed itself to be a prognostic marker in terms of clinically important features, namely survival rates and response to treatment. CTC concentration was significantly associated with the overall survival and progression-free survival rates. A strong association between the overall survival or progression-free survival rate and CTC concentration could be observed. Variant-7 androgen receptors-positive (AR-V7-positive) patients showed a poor response to androgen receptor signaling (ARS) inhibitors, but this did not compromise their response to taxanes. In localized PC, only positive Cluster of Differentiantion 82 protein (CD82+) correlated with a higher survival rate. CTC count and AR-V7 expression showed itself to be a valuable biomarker for survival in metastatic PC and response to ARS-inhibitors. CTC diagnostic performance for localized PC or for screening and early detection is not high enough to show additional value over the other biomarkers.
本综述的目的是总结循环肿瘤细胞（CTC）在临床实践中应用的最新数据。我们在过去五年中使用两个数据库（Medline和Scopus）进行了系统的文献检索，并使用了以下检索词：（CTC或“循环肿瘤细胞”或“液体活检”）以及前列腺。主要结局是CTC对前列腺癌（PC）进展和生存的预测价值。次要结局是CTC对治疗反应的预测价值以及取决于评估方法的CTC检测结果。在转移性PC中，CTC计数在临床重要特征（即生存率和对治疗的反应）方面显示为一种预后标志物。CTC浓度与总生存率和无进展生存率显著相关。可以观察到总生存率或无进展生存率与CTC浓度之间存在强关联。变异体7雄激素受体阳性（AR-V7阳性）患者对雄激素受体信号传导（ARS）抑制剂反应较差，但这并不影响他们对紫杉烷类药物的反应。在局限性PC中，只有分化簇82蛋白阳性（CD82+）与较高的生存率相关。CTC计数和AR-V7表达在转移性PC的生存以及对ARS抑制剂的反应方面显示为有价值的生物标志物。CTC对局限性PC或筛查及早期检测的诊断性能不足以显示出比其他生物标志物更高的附加价值。
